News

News
Partner news

Philogen announces new collaboration with Janssen to discover small molecule therapeutics

Read full story
Partner news

Ultromics Announces Collaboration with Janssen to Develop AI for Patients with Amyloidosis with Cardiac Involvement

Read full story
Partner news

F-star Therapeutics Announces License Agreement with Janssen to Develop and Commercialize Multiple Next Generation Bispecific Antibody Therapeutics

Read full story
JNJ Press releases

Johnson & Johnson Innovation becomes a leading partner of Sitem Startup Club

Read full story
Partner news

Whole Genome Sequencing data on 200,000 UK Biobank participants are made widely available for research

Read full story
Partner news

Persephone Biosciences Inc. Announces Collaboration with Janssen Biotech, Inc.

Read full story
JNJ Press releases

LAVA THERAPEUTICS PROVIDES BUSINESS UPDATE AND REPORTS SECOND QUARTER RESULTS

Read full story
JNJ Press releases

New report reveals strength of the UK’s thriving genomics sector

Read full story
JNJ Press releases

MESTAG THERAPEUTICS EXTENDS SEED FINANCING TO $45 MILLION AND WELCOMES NEW INVESTORS FORBION, GV (FORMERLY GOOGLE VENTURES) AND NORTHPOND VENTURES

Read full story
JNJ Press releases

Johnson & Johnson Innovation Announces Extension Of Innovation Partnering Office at Monash University In Collaboration With Victorian State Government To Accelerate The Life-Sciences Hub

Read full story
Partner news

Apollo Therapeutics Completes $145 Million Financing Led by Patient Square Capital to Expand and Advance Portfolio-Based Drug Development

Read full story
Partner news

Mestag Therapeutics announces collaboration with Janssen, focused on the discovery of novel fibroblast targets for the treatment of inflammatory disease

Read full story
Partner news

L'engagement de Janssen France dans l'IA et la génomique

Read full story
Partner news

Collaboration with Johnson & Johnson Innovation to jump-start search for new malaria drugs

Read full story
Partner news

Teneobio Announces Achievement of Milestone Payment as Janssen Advances Phase I Study of Bispecific JNJ-75348780 for the Treatment of NHL and CLL

Read full story